Chimerix, Inc. , a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today provided a year-end recap of 2014 highlights for the investigational oral broad-spectrum antiviral brincidofovir. M. Michelle Berrey, M.D., M.P.H., President and CEO of Chimerix, said, "2014 was a pivotal year for brincidofovir and for Chimerix.
http://ift.tt/1AWCJjj
http://ift.tt/1AWCJjj
No comments:
Post a Comment